Faculty, Staff and Student Publications
Publication Date
6-14-2024
Journal
Med
DOI
10.1016/j.medj.2024.05.001
PMID
38878765
PMCID
PMC12004455
PubMedCentral® Posted Date
6-14-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
Keywords
Humans, Uterine Cervical Neoplasms, Female, Antibodies, Monoclonal, Humanized, Chemoradiotherapy, Immunotherapy, Immune Checkpoint Inhibitors, Randomized Controlled Trials as Topic
Published Open-Access
yes
Recommended Citation
Jeffrey A How and Amir A Jazaeri, "Immunotherapy in Locally Advanced Cervical Cancer: Integrating Keynote-A18 Into Management Strategies" (2024). Faculty, Staff and Student Publications. 4540.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4540
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons